8 位分析师一致给予 Spruce Biosciences “持有”评级，其第二季度每股收益为 -0.22 美元，超出预期。 8 analysts give Spruce Biosciences a consensus "Hold" rating, and its Q2 EPS was -$0.22, beating estimates.

八位分析师对Spruce Biosciences公司进行了调查, 这是一家专注于罕见内分泌疾病的生物制药公司, 分析师给了该公司一个共识性"持有"评级, 8 analysts covering Spruce Biosciences, a biopharmaceutical firm focused on rare endocrine disorders, have given it a consensus "Hold" rating, with 6 analysts assigning a hold and 2 assigning a buy. 一年平均价格目标是5.00美元。 The average 1-year price target is $5.00. Q2每股收入为 - 0.22美元,比重估计为 - 0.32美元。 Q2 earnings per share were -$0.22, beating estimates of -$0.32. 该公司正在研制一种非类固醇疗法,用于第2b阶段临床试验中的先天性肾上腺增生。 The company is developing a non-steroidal therapy for congenital adrenal hyperplasia in Phase 2b clinical trials.